Aclaris Therapeutics Shares Tumble Following Quarterly Report
Published on 11/11/2025 at 10:13 | Redaktion boerse-global.de
Aclaris Therapeutics witnessed a significant selloff in its stock price after releasing disappointing third-quarter 2025 financial results. The biotechnology firm reported a net loss of $14.6 million, representing nearly double the $7.6 million loss recorded during the same period last year. Revenue also declined substantially, falling to $3.3 million from the previous year’s $4.3 million. These figures indicate a notable acceleration in the company’s operational cash burn rate.
Investors responded decisively to the financial update, driving shares down more than 8% to $2.13. The stock has declined 14% year-to-date, maintaining extreme volatility throughout the past twelve months with trading ranging between $5.17 and $1.05. While the company maintains $167 million in liquidity, projected to fund operations through 2028, management’s credibility Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
